Zealand Pharma has entered a collaboration with Roche Diabetes Care for the Phase 3 trials with dasiglucagon for treatment of congenital hyperinsulinism (CHI).    Zealand is responsible for conducting the Phase 3 trials, while Roche Diabetes Care provides its Accu-Chek® Combo pump system for this study under the terms of the agreement.    Britt Meelby Jensen, president and chief executive officer of Zealand, said, “We are pleased to work with Roche Diabetes Care products fo...